Final NHS green light for Roche’s Kadcyla
The drug will be funded as an option for treating patients with HER2-positive early breast cancer
Read More
Tag: trastuzumab emtansine
NICE backs Roche’s Kadcyla for HER2-positive early breast cancer
Around 800 people will be eligible for treatment with Kadcyla
Read More
Roche submits FDA supplemental biologics license application for Kadcyla
Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla to include the adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Read More
Major u-turn sees Roche’s Kadcyla backed for NHS use
In a major turnaround Roche’s Kadcyla will now become routinely available on the NHS to some patients with breast cancer after a confidential deal was reached between the drug giant and NHS England.
Read More
SMC u-turn backs Roche’s Kadcyla for breast cancer
Women in Scotland will be among the first in the UK to have routine NHS access to Roche’s breast cancer drug Kadcyla after a landmark u-turn by cost regulators endorsed funding for the drug.
Read More
NICE backs Roche’s Perjeta, but bars Kadcyla
Patients with certain forms of breast cancer should be able to get routine NHS access to Roche’s Perjeta in England and Wales in the next three months following a recent final nod from NICE, but Kadcyla has been rejected by the cost regulator.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
